Literature DB >> 10360677

Radioimmunoluminography: a tool for relating tissue antigen concentration to clinical outcome.

G Boxer1, S Stuart-Smith, A Flynn, A Green, R Begent.   

Abstract

Proteins control cell function and measurement of their concentration is crucial for understanding their roles in health and disease. However, current methods for their detection in tissue sections are not quantitative. Radioimmunoluminography (RILG) is a system for direct measurement of quantity and distribution of protein in histological sections. Histological carcinomas were reacted with antigen-saturating concentrations of 125I-antibody to carcinoembryonic antigen (CEA). Antibody distribution and concentration was mapped by phosphor imaging. Radioactivity in each pixel of the digital image was proportional to antigen concentration, calculated from a standard line generated from a nitrocellulose CEA dot-blot assay. RILG gave a linear correlation with standards of known CEA concentration (r = 0.999). Six tumour xenografts with differing CEA concentrations by radioimmunoassay (RIA) were studied by RILG and immunohistochemistry (IHC). RILG gave a linear correlation with CEA by RIA (r = 0.994) but IHC failed to do so (r = 0.42). CEA levels measured by RILG, in cryostat (n = 15) and paraffin (n = 19) sections from colorectal cancer patients showed a range of CEA concentration (38.9-594 ng g(-1) and 22.5-212.5 ng g(-1) respectively). Tumour CEA concentration by RILG was significantly correlated with dose of antibody (% injected radioactivity kg(-1)) localized in tumour (P = 0.04 and P < 0.02 respectively), in patients receiving radioimmunoguided surgery. Clinical relevance of RILG is illustrated by identifying patients with high tumour CEA, most likely to benefit from antibody targeted therapy. Knowledge of the pathophysiology of many diseases may be enhanced by quantitative estimation of antigen concentration related to tissue morphology.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10360677      PMCID: PMC2362277          DOI: 10.1038/sj.bjc.6690443

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

Review 1.  Penetration of tumor tissue by antibodies and other immunoproteins.

Authors:  T R Shockley; K Lin; J A Nagy; R G Tompkins; H F Dvorak; M L Yarmush
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

2.  Autoradioluminography, a novel quantitative method of TLC-autoradiography.

Authors:  M Okuyama; Y Hatori; A Shigematsu
Journal:  Biol Pharm Bull       Date:  1994-05       Impact factor: 2.233

Review 3.  Biological approaches to the controlled delivery of drugs: a critical review.

Authors:  M J Poznansky; R L Juliano
Journal:  Pharmacol Rev       Date:  1984-12       Impact factor: 25.468

4.  Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents.

Authors:  R B Pedley; J A Boden; R Boden; G M Boxer; A A Flynn; P A Keep; R H Begent
Journal:  Cancer Res       Date:  1996-07-15       Impact factor: 12.701

5.  Tumor concentration and distribution of carcinoembryonic antigen measured by in vitro quantitative autoradiography.

Authors:  J K Chung; J J Jang; D S Lee; M C Lee; C S Koh
Journal:  J Nucl Med       Date:  1994-09       Impact factor: 10.057

6.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

7.  Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma--implications for radioimmunotherapy.

Authors:  G M Boxer; R H Begent; A M Kelly; P J Southall; S B Blair; N A Theodorou; P M Dawson; J A Ledermann
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

8.  Comparison of anti-fetal colonic microvillus and anti-CEA antibodies in peroperative radioimmunolocalisation of colorectal cancer.

Authors:  S D Blair; N A Theodorou; R H Begent; P M Dawson; M Salmon; S Riggs; A Kelly; G Boxer; P Southall; P Gregory
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

9.  Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies.

Authors:  D M Lane; K F Eagle; R H Begent; L D Hope-Stone; A J Green; J L Casey; P A Keep; A M Kelly; J A Ledermann; M G Glaser
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

10.  Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody.

Authors:  D Marshall; R B Pedley; R G Melton; J A Boden; R Boden; R H Begent
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

View more
  1 in total

1.  Anti-tumoral potential of a human granulysin-based, CEA-targeted cytolytic immunotoxin.

Authors:  Raquel Ibáñez-Pérez; Patricia Guerrero-Ochoa; Sameer Al-Wasaby; Rocío Navarro; Antonio Tapia-Galisteo; Diego De Miguel; Oscar Gonzalo; Blanca Conde; Luis Martínez-Lostao; Ramón Hurtado-Guerrero; Laura Sanz; Alberto Anel
Journal:  Oncoimmunology       Date:  2019-07-22       Impact factor: 8.110

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.